Methylprednisolone administration in multiple sclerosis patients (pulsed therapy) resulted in clinical improvement that showed a correlation to NF-kB inhibition.

The publication:

[stextbox id="grey"]

J Neurol Sci. 2008 Jan 15;264(1-2):145-50.

Changes in the activation level of NF-kappa B in lymphocytes of MS patients during glucocorticoid pulse therapy.

Eggert M, Goertsches R, Seeck U, Dilk S, Neeck G, Zettl UK.

Department of Internal Medicine, Rostock Clinic South, Südring 81, 18059 Rostock, Germany.

Summary of the abstract

Nuclear factor-kappaB activity was analyzed in 24 multiple sclerosis (MS) patients during the course of a methylprednisolone pulse therapy.

All patients responded to treatment. The mean level of DNA-binding p65 in MS was proportionate to that of healthy controls, but was significantly decreased directly after therapy whereas the level of DNA-binding p50 was significantly elevated prior to therapy and remained unchanged. In summary, pulse therapy resulted in a decreased level of activated p65 NF-kappaB subunits leading to decreased levels of transcriptionally active pro-inflammatory NF-kappaB.

[/stextbox]